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Abstract The process involving a rearrangement of pyrrolidino[3,4-
c]pyrrolidine to another pyrrolidino[3,4-b]pyrrolidine involving sodium 
methoxide as base is fully studied. The effects of the substituents are analyzed 
during the ring-opening ring-closing sequence. Computational studies are also 
performed to explain the importance of susbstituents and quaternary carbons, 
especially when the (3-indolyl)methyl  is present in the starting material. 
Finally, all the samples are evaluated as potential candidates as antibacterial 
and antimycobacterial agents. 
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Introduction 
The design of very simple molecular architectures with the 
broadest biological and medicinal coverage is always pursued, 
and especially for the long treatment of degenerative illnesses. A 
clear example is represented by succinimides.1  Activities such as 
CNS depressant, analgesic, antitumor, antispasmodic, 
bacteriostatic, hypotensive, antibacterial, antifungal, anti-
tubercular, etc., have been reported in the literature.1,2,3 
Succinimides are easily available from succinic acid or succinic 
anhydride and their derivatives involving ring-opening/ring-
closing strategies.1,4 However, the imido group and the double 
bond of maleimides offer new substitution patterns. For example, 
their electrophilic character made them excellent dienophiles in 
Diels-Alder reactions and dipolarophiles in 1,3-dipolar 
cycloadditions.5  In fact maleimides are frequently used for the 
optimization of this cycloaddition processes. 
During our investigation of the synthesis of new derivatives 
with a thiohydantoin framework6 (similar to 2) with anti-
tuberculosis and anti-bacterial activity,7,8 we discovered the 
formation of unexpected compounds, which resulted from a 
rearrangement of the succinimide in the presence of sodium 
methoxide. The result of this rearrangement is a chemical switch 
in which from one fused succinimide with a 
tetrahydropyrrolo[3,4-c]pyrrole skeleton 1 it was possible 
access to a new succinimide with tetrahydropyrrolo[3,4-
b]pyrrole framework 3 (Scheme 1).  
 
 
Scheme 1 First evidence of the titled succinimide rearrangement 
 
In this work we thoroughly study the mechanism of the 
particular rearrangement originated by the methoxide anion, 
which attack to molecules 4 to give products 5 (Scheme 2).6 We 
envisage the possible scope and its utility in synthetic organic 
chemistry and as antituberculosis and antibacterial agent.7 
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Scope of the rearrangement and structural determination of 
compounds 5, 6 and 7. 
Following the reaction conditions found in the confirmation 
of the structure of compound 5 (Ar, R1 = Ph, R2 = 3-indolyl) in our 
previous publication,6 we started with the analysis of the 
tetrahydropyrrolo[3,4-c]pyrrole 4a obtained from 1,3-dipolar 
cycloaddition of the corresponding methyl 
benzylideneaminoglycinate with N-methylmaleimide (NMM), 
(see experimental part). Under general conditions described in 
Scheme 2, compound 4a afforded a very complex mixture of 
unidentified products detected by 1H NMR experiment of the 
crude reaction mixture. 
 
 
Scheme 2 Succinimide rearrangement studied in this work 
 
Cycloadducts 4b-4f, obtained from imino esters derived from 
leucine and phenylalanine were submitted to conditions depicted 
in Scheme 2, obtaining the corresponding tetrahydropyrrolo[3,4-
b]pyrroles 5b-f in moderate yield (up to 54%, Figure 1). Despite 
purifying all these compounds in deactivated flash silica gel, we 
observed some decomposition/epimerization during this 
process. We also discovered that they were not stable under 
storage for more than one week at -20 °C.  
 
 
Figure 1 Succinimide rearrangement observed in compounds 4a-4f 
 
According to our experience,8 the introduction of an indol 
ring can be beneficial for increasing the biological effect of the 
substance.9 With this aim, cycloadducts 4g, derived from 
tryptophan, were prepared (see experimental part) and were 
allowed to undergo the titled stereospecific rearrangement. 
Again, the reaction proceeded regio- and stereospecifically to 
give the corresponding compounds 5g10 in very high yields (70-
98 %) (Scheme 3). These series of molecules 5g are very stable 
and could be stored for a long time. 
The preparation of N-benzoylcarbothioamides 6g was 
achieved smoothly by reaction of 5g with benzoylisothiocyanate 
in acetonitrile at room temperature for 24-30 h (Scheme 3). The 
incorporation of this unit to the pyrrolidine ring increases the 
biological potency of the precursor heterocycles. 
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Scheme 3 Synthetic 4g→5g→6g sequence involving (3-indolyl)methyl 
derivatives 
 
The relative configuration of all new racemic compounds was 
stablished according to data acquired using NMR experiments 
and by single crystal X-ray diffraction analysis for the compound 
6gf (Figure 2). 
 
 
Figure 2 X-Ray diffraction analysis of compound 6gf. Thermal ellipsoids are 
drawn at 40% probability level.11 
A larger excess of sodium methoxide in methanol (not dry) 
furnished the same arrangement (under identical reaction 
conditions) afforded free betaproline amino acid12 derivative 
(possessing a zwitterionic structure) 7gg in almost quantitative 
yield (Scheme 4). The structure of its skeleton was also confirmed 
by X-ray diffraction analysis demonstrating that epimerization 
occurred only in the carbon atom 4. 
 
 
Scheme 4 Sythesis of betaproline derivative 7gg and its X-ray diffraction 
analysis pattern.13 
Study of the mechanism by DFT calculations. 
At this point we can argue that the presence of a quaternary 
carbon at 2-position in the prolinate ring of compounds 4 seems 
to be crucial for the development of the arrangement in basic 
media. The Thorpe-Ingold effect can justify the scarce reactivity 
of cycloadduct 4a and the moderate to excellent yields achieved 
in substrates 4b-g. Additionally, the presence of the (3-
indolyl)methyl residue at this position accelerated the process 
and gave an extra stability to the final compounds. We decided to 
perform computational calculations within the DFT framework 
in order to better understand the reaction mechanism associated 
with succinimide 4 rearrangement and its subsequent 
isomerization to yield compounds 5. For that, we selected 4ga as 
model compound. In the first part of this study we analyzed all 
the possible reactions of methoxide anion with 4ga. This anion 
can act as a nucleophile, reacting with the CO double bond of the 
imido groups (TS1 and TS1’ in Figure 4). On the other hand, 
methoxide can also act as base, therefore the abstraction the 
protons in α position of the imido groups of maleimide moiety 
were also considered (Figure 3).  
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Figure 3 Possible reactions of compound 4ga with methoxide anion. Acidic 
hydrogens considered are highlighted in green 
 
The main geometrical features of the transition structures 
associated with these processes and their relative energies are 
collected in Figure 4. 
 
 
Figure 4 Main geometrical features and relative activation and free Gibbs 
energies (between brackets) associated with the possible reactions of 
methoxide anion with computed at B3LYP-D3(PCM)/6-31+G* level at 298.15 
K. Distances and energies are in Å and kcal mol-1, respectively. Non-relevant 
hydrogen atoms are omitted for clarity 
 
Our calculations shown that the activation energy barriers 
associated with the methoxide addition are lower than the 
deprotonation ones. This difference is even smaller considering 
Gibbs free activation barriers. However, the corresponding 
enolates formed are high in energy, consequently, their 
formation is thermodynamically disfavored. Therefore, any 
possible isomerization of compound 4ga via direct proton 
abstraction will not be further considered in this study. In 
addition, calculations also show that bridged ring formation is 
also kinetically disfavored (See supporting information for 
further details about other possible reaction paths 
computationally analyzed). Within these results, we next 
analyzed the succinimide rearrangement processes leading 
towards formation of fused rings 5. The relative and activation 
energies (and Gibbs free energies) computed are collected in 
Scheme 5. The main geometrical features of the corresponding 
transition structures are depicted in Figure 5.  
 
 
Scheme 5 Activation and relative energies (and Gibbs free energies between 
brackets) associated with 4ga rearrangement with methoxide anion computed 
at B3LYP-D3 / 6-31+G(d) level of theory at 298 K. Energies are in kcal mol-1 
 
Figure 5 Main geometrical features and relative activation and free Gibbs’ 
energies (between brackets) associated with 4ga rearrangement. See caption 
of Figure 3 for further details 
 
Within the proposed mechanism, formation of the new 
maleimide ring is the rate-limiting step (TS3a has activation 
barrier ca. 1 kcal mol-1 higher than any other step). Moreover, 
calculations show that formation of INT4a is thermodynamically 
disfavored.  
Once formation of INT4a via ring–opening ring–closing 
mechanism was assessed, we next analyzed computationally the 
subsequent isomerization towards ring–fused 5ag. Relative and 
activation energies (and Gibbs free energies) and main 
geometrical features of the corresponding transition structures 
are collected in Scheme 6. 
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Scheme 6 Activation and relative energies (and Gibbs free energies between 
brackets) associated with 5ga formation. See caption of Figure 3 for further 
details 
Our calculations indicate that the isomerization of INT4a 
towards 5ga formation is thermodynamically favored, as 
reflected by its stability. Geometry inspection revealed that 
INT4a is highly energetic structural arrangement due to the 
repulsion associated with the eclipsed conformation of 
methoxycarbonyl and maleimide moieties. That repulsion is 
dismissed due to the isomerization process, being replaced by a 
stabilizing π,π-stacking interaction with the 3-indolyl moiety, 
and a close indole-ester hydrogen bonding, thus making this step 
the driving force of the reaction (Figure 6). Remarkably, the 
activation barriers associated with the proposed mechanism are 
lower than 6 kcal mol-1, compatible with the relatively mild 
conditions experimentally required (reaction temperature of 65 
°C). These stabilizing interactions, which did not exist in 
compounds 5b-f, can be the reasons of the 
epimerization/decomposition of these last molecules.  
 
 
Figure 6 Optimized structures of INT4a and 5ga 
 
Anti-mycobacterial Activity.  
Anti-mycobacterial activity of prepared compounds were 
tested against M. tuberculosis H37Rv strain using Microplate 
Alamar Blue assay according to literature method14 measured by 
means of MIC values (µg/mL). Ethambutol (EMB) (Sigma E4630) 
and isoniazid (INH) (Sigma I3377) were used as standard 
reference drugs. The Anti-TB activity against M. tuberculosis 
H37Rv strain showed moderate activity, in the range of 10-
80µg/mL, when compared to isoniazid and ethambutol as known 
reference drugs (Table 1). Especially the compounds 4gf 
(possess -CI on the phenyl ring and -Me on the melaimide ring) 
revealed the highest activities with the MIC values of 10 µg/mL 
whereas the compound 4ga, 4gc, 4ge, 6gd and 7gg showed 
activity in value of 20-40 µg/mL and the others compounds 
showed the lowest activities with the MIC values of 80 µg/mL. In 
addition the tested compounds exhibited better anti-TB activity 
when compared their anti-bacterial activity as indicated in Table 
1. Although the mode of action or biological target of these 
molecules is unknown at the moment, further work to get more 
potent derivatives is under investigation. 
 
Anti-bacterial Activity.  
Antibacterial activity of prepared compounds were tested 
against two Gram(+) bacteria Staphylococcus aureus (ATCC 
25925), Bacillus subtilis (ATCC 6633) and three Gram(-) bacteria 
Escherichia coli (ATCC 25923), Acinetobacter baumannii (ATCC 
02026), Aeromonas hydrophila (ATCC 95080) which obtained 
from the Refik Saydam Hıfzısıhha Institute, Ankara, Turkey. 
Ampicillin was used as control drug. The minimum inhibitory 
concentrations (MIC) values was determined by agar dilution in 
duplicate as recommended by the Clinical Laboratory Standards 
Institute.15 To ensure that the solvents had no effect on microbial 
growth, a control test was performed containing inoculated broth 
supplemented with DMSO at the same dilutions used for the test 
compounds and was determined to be inactive. 
 The tested compounds inhibited the growth of bacteria at MIC 
values in the range of 62.5-500 µg/mL whereas the control, 
ampicillin, showed activity against the tested bacterıa with a 
range of 125-0.9 µg/mL as given in Table 1. It is also important to 
note that the screened compounds were found to show the better 
activity against A.baumannii (ATCC 02026) in the range of 62.5-
125 µg/mL whereas the control ampicillin showed activity in MIC 
values of 125 µg/mL. 
 
Table 1. The MIC values (µg/mL) of the tested compounds against the bacterial and mycobacterial strains. 
 
 S. aureus (ATCC 
25925) 
E. coli (ATCC 
25923) 








4ga 250 125 62,5 125 125 20  
4gb 125 125 125 125 125 80 
4gc 125 125 62,5 125 125 40 
4gd 250 125 62,5 125 125 80 
4ge 125 125 62,5 125 125 40 
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4gf 125 125 62,5 62,5 62,5 10 
5gd 125 125 62,5 125 62,5 80 
6ga 125 125 125 125 125 80 
6gb 250 250 125 250 250 80  
6gd 250 250 125 250 500 31.25 
6ge 125 125 125 125 125 80  
6gf 125 250 125 125 125 80  
7gg 62,5 125 62,5 125 62,5 40  
Ampicillin 31.25 15.62 125 0.9 31.25  
Isoniazid      0.2 and 0.1 
Etambuol      5 and 10 
 
Conclusions 
The rearrangement of tetrahydropyrrolo[3,4-c]pyrrole 
skeleton to a new tetrahydropyrrolo[3,4-b]pyrrole structure 
could be efficiently controlled in basic media. The presence of 
quaternary carbons in the starting bicyclic succinimide favored 
the rearrangement. The presence of the (3-indolyl)methyl group 
attached to this quaternary carbon is crucial for the stability of 
the final rearranged succinimides, increasing the biological 
activity of this family of compounds. Calculation predictions were 
in agreement with the experimental findings: first, the methoxide 
anion attacked the carbonyl group rather than promote the 
deprotonation; second, the spontaneous isomerization afforded 
a much more stable compound; third, a stabilizing π-stacking 
interaction between the indole ring and the ester group bonded 
to the epimerized carbon atom was the driving force of the 
reaction. Compound 4gf was the most active compound after the 
evaluation of all biological tests. 
Experimental Section 
The commercially available reagents for syntheses and 
analyses were obtained with analytical grade and used as 
received. Column chromatography was performed on silica gel 
60 (Merck, 230-400 mesh). Melting points were determined with 
a Reichert Thermovar hot plate apparatus and are uncorrected. 
Mass spectra were obtained using a Bruker AC-300 or AC-400, 
and were recorded at 300 or 400 MHz for 1H NMR and 75 or 100 
MHz for 13C NMR using CDCl3 and MeOD as a solvent. Chemical 
shifts are given in parts per million (δ:) downfield from 
tetramethylsilane. The following abbreviations are used: s – 
singlet; d – doublet; t – triplet; q – quartet; m – multiplet; br – 
broad. IR spectra were taken on a Perkin-Elmer Spectrum One 
FT-IR spectrometer and also were taken on Nicolet 510 P-FT. 
Low-resolution electron impact (EI) mass spectra were obtained 
at 70 eV using a Shimadzu QP-5000 by injection or DIP; fragment 
ions in m/z are given with relative intensities (%) in parentheses. 
High-resolution mass spectra (HRMS) were measured on an 
instrument using a quadrupole time-of-flight mass spectrometer 
(QTOF) and also through the electron impact mode (EI) at 70 eV 
using a Finnigan VG Platform or a Finnigan MAT 95S.The 
compounds are named according to the IUPAC system; names 
were obtained using MDL Autonom. 
The known pyrrolidine derivative methyl (1S,3R)-1-((1H-
indol-3-yl)methyl)-4,6-dioxo-3,5-
diphenyloctahydropyrrolo[3,4-c]pyrrole-1-carboxylate (4ga) 
and and aminocarbothiol pyrrolidine derivatives 
(2S,3S,3aS,6aR)-Methyl 6a-((1H-indol-3-yl)methyl)octahydro-
4,6-dioxo-2,5-diphenylpyrrolo[ 3,4-b]pyrrole-3-carboxylate 
(5ga) were prepared as from literature. 16,6 
Novel bicyclic pyrrolidine derivatives 4gb-4gf were prepared by 
modification of literature methods.17,6 
 
Computational Methods 
Theoretical calculations have been carried out at the B3LYP-
D3/6-31+G(D)18 level by using the GAUSSIAN 0919 suite of 
programs. Activation and relative (Gibbs) energies were 
computed within the DFT framework20 at the B3LYP-D3/6-
31+G(D) level at 298K in which dispersion corrections are 
included by means of Grimme’s D3 model.21 Solvent effects were 
estimated by the polarization continuum model22 (PCM) method 
within the self-consistent reaction field (SCRF) approach.23 All 
SCRF-PCM calculations were performed using dimethylsulfoxide 
(ε= 46.826) as model solvent. Merz-Kollman atomic radii cavities 
(as invoked by the radii= Pauling keyword) were used in reaction 
steps associated with hydrogen atom migration. 
All the stationary points were characterized by harmonic 
vibrational analysis. Local minima showed positive definite 
Hessians. Fully optimized transition structures (TSs) showed one 
and only one imaginary frequency associated with nuclear 
motion along the chemical transformation under study. Reaction 
paths were checked by Intrinsic Reaction Coordinate (IRC) 
calculations. In order to avoid errors associated with 1N 
solvation state, activation barriers were compute comparing 
energies of directly connected stationary points. 
 
General procedure for Preparation of pyrrolidines 
To a solution of the silver salt (AgOAc) in toluene (3 mL) was 
added a solution of imino ester (1 mmol) and N-phenylmaleimide 
(1 mmol) in toluene (2 mL). To the resulting suspension 
trimethylamine (0.05 mmol, 7 µL) was added and the mixture 
stirred at room temperature (20-30 ºC) for 18-24 h. The crude 
reaction mixture was filtered through a small Celite path. The 
residue was purified by flash chromatography or the solid 
products were recrystallized in mixture of n-hexane/ether. 
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General procedure for rearrangement access to pyrrole-4,6-
diones  
To a stirred solution of bicyclic pyrrolidine 4a-4f (1 mmol) in 
dry methanol (10 mL) was added dropwise a solution of sodium 
methoxide (1.2 mmol) in dry methanol (10 mL) over 10-15 min, 
and the mixture stirred and refluxed for 32-36 h. The solvent was 
evaporated under reduced pressure and quenched with 
saturated aqueous ammonium chloride, then extracted with 
dichloromethane (3x15 mL). The combined organic phases were 
dried over MgSO4 and filtered. The product 5b-5f were purified 
by flash chromatography, the silica gel was deactivated (a 5% of 




(4a): After 18 hours and work up the product was isolated as a 
white solid (318 mg, 91 % yield); column chromatography (n-




(4b): After 18 hours and work up the product was isolated as a 
white solid  (321 mg, 79 % yield); column chromatography (n-
hexane:EtOAc; 8:2); mp: 145-149 ºC; IR (ATR) υmax: 1713, 1502, 
1375, 1206, 1166, 1140, 854, 702, 692 cm-1;  1H NMR (300 MHz, 
CDCl3): δ 0.89 (d, J = 6.5 Hz, 3H), 1.01 (d, J = 6.5 Hz, 3H), 1.69-1.87 
(m, 2H), 2.01-2.19 (m, 1H), 2.81 (d, J = 7.2 Hz, 1H, NH), 3.38 (d, J 
= 7.6 Hz, 1H), 3.76 (dd, J = 9.3, 7.6 Hz, 1H), 3.83 (s, 3H, OCH3), 4.72 
(dd, J = 9.2, 7.1 Hz, 1H), 7.01-7.10 (m, 2H, Ar-H), 7.25-7.48 (m, 8H, 
Ar-H) ppm; 13C NMR (75 MHz, CDCl3): δ 22.2 (CH3), 24.4 (CH3), 
24.7 (CH), 43.2 (CH2), 50.3 (CH), 52.5 (CH3), 56.4 (CH), 62.3 (CH), 
70.5 (C), 126.1, 127.2, 128.5, 128.6, 128.7, 129.1, 131.6, 137.1 
(Ar-C), 172.8 (C=O), 173.8 (C=O), 174.8 (C=O) ppm; MS (EI): m/z 
350 (M+-C4H9, 21%), 349 (50), 347 (100), 233 (16), 202 (10), 190 
(50), 170 (11), 147 (11), 143 (13), 130 (14), 115 (10), 103 (15). 
HRMS (DIP): m/z [M+] calculated for C24H26N2O4, 406.1893; 
found: 406.1905.  
Methyl 6a-isobutyl-4,6-dioxo-2,5-
diphenyloctahydropyrrolo[3,4-b]pyrrole-3-carboxylate 
(5b): After 36 hours and work up the product was isolated as a 
sticky yellow oil (211 mg, 52 % yield); column chromatography 
(silica gel deactivate with 5% Et3N) (n-hexane:EtOAc; 8:2); IR 
(ATR) υmax: 29254, 2922, 1709, 1495, 1378, 1235, 1191, 734, 702, 
690, 617, 586 cm-1; 1H NMR (300 MHz, CDCl3): δ 0.98 (d, J = 6.5 
Hz, 3H), 1.07 (d, J = 6.5 Hz, 3H), 1.79-1.98 (m, 2H), 2.10-2.19 (m, 
1H), 3.64 (dd, J = 4.7, 3.3 Hz, 1H), 3.76 (d, J = 3.3 Hz, 1H), 3.79 (s, 
3H, OCH3), 4.79 (d, J = 4.7 Hz, 1H), 6.80-6.90 (m, 2H, Ar-H), 7.23-
7.67 (m, 8H, Ar-H) ppm; 13C NMR (75 MHz, CDCl3): δ 23.4 (CH3), 
24.3 (CH3), 25.6 (CH), 43.2 (CH2), 51.2 (CH), 52.9 (CH3), 54.7 (CH), 
65.8 (CH), 69.9 (C), 126.4, 128.1, 128.8, 128.9, 129.1, 131.8 (Ar-
C), 173.1 (C=O), 175.9 (C=O), 178.2 (C=O) ppm; MS (EI): m/z 350 
(M+-C4H9, 36%), 318 (13), 200 (94), 191 (20), 177 (100), 171 
(13), 144 (21), 143 (14), 119 (14), 91 (21). HRMS (DIP): m/z [M+] 
calculated for C24H26N2O4, 406.1893; found: 406.1868.  
Methyl 1-isobutyl-4,6-dioxo-5-phenyl-3-(pyridin-2-
yl)octahydropyrrolo[3,4-c]pyrrole-1-carboxylate (4c): After  
18 hours and work up the product was isolated as a white solid  
(350 mg, 86 % yield); column chromatography (n-hexane:EtOAc; 
6:4); mp: 171-175 ºC. IR (ATR) υmax: 1705.7, 1387, 1248, 1207, 
1151, 1181, 764, 728, 691 cm-1; 1H NMR (300 MHz, CDCl3): δ 0.88 
(d, J= 6.6 Hz, 3H), 1.01 (d, J= 6.7 Hz, 3H), 1.69 (dd, J= 14.1, 4.7 Hz, 
1H), 1.81-1.97 (m, 1H), 2.16 (m, 1H), 3.46 (d, J = 7.6 Hz, 1H), 3.70 
(dd, J = 9.0, 7.6 Hz, 1H), 3.86 (s, OCH3), 4.70 (d, J = 9.0 Hz, 1H), 
7.02-7.25 (m, 3H, Ar-H), 7.30-7.49 (m, 4H, Ar-H), 7.68-7.73 (m, 
1H, Ar-H), 8.34-8.65 (m, 1H, Ar-H) ppm; 13C NMR (75 MHz, 
CDCl3): δ 22.1 (CH3), 24.4 (CH3), 25.0 (CH), 44.3 (CH2), 51.7 (CH), 
52.6 (CH3), 58.5 (CH), 65.0 (CH), 72.2 (C), 123.7, 123.9, 126.6, 
128.7, 129.1, 131.9, 136.9, 149.4, 155.5 (Ar-C), 172.33 (C=O), 
174.5 (C=O) 174.8 (C=O) ppm; MS (EI): m/z 408 (M+ 12%), 407 
(47), 351 (14), 350 (24), 349 (23), 348 (100), 177 (10), 175 (41), 
171 (17), 145 (18), 131 (13). HRMS (DIP): m/z [M+] calculated 
for C23H25N3O4: 407.1845; found: 407.1851.  
Methyl 6a-isobutyl-4,6-dioxo-5-phenyl-2-(pyridin-2-
yl)octahydropyrrolo[3,4-b]pyrrole-3-carboxylate (5c): After 
37 hours and work up the product was isolated as a sticky yellow 
oil (157 mg, 40 % yield); column chromatography (silica gel 
deactivate with 5% Et3N) (n-hexane:EtOAc; 6:4); IR (ATR) υmax: 
3321, 2957, 2925, 1709, 1593, 1375, 1191, 1138, 749, 690, 599 
cm-1;  1H NMR (300 MHz, MeOD): δ 0.94 (d, J= 6.5 Hz, 3H), 1.02 (d, 
J= 6.6 Hz, 3H), 1.72-1.99 (m, 2H), 2.02-2.23 (m, 1H), 3.79-3.83 (m, 
1H), 3.93 (d, J = 2.7 Hz, 1H), 4.93 (d, J = 3.3 Hz, 1H), 6.73-6.94 (m, 
2H, Ar-H), 7.20-7.43 (m, 4H, Ar-H), 7.60 (d, J = 7.9 Hz, 1H, Ar-H), 
7.69-7.74 (m, 1H, Ar-H), 8.40-8.46 (m, 1H, Ar-H) ppm; 13C NMR 
(75 MHz, MeOD): δ 24.0 (CH3), 24.7 (CH3), 26.5 (CH), 45.4 (CH2), 
53.5 (CH), 57.4 (CH), 68.3 (CH), 71.8 (C), 122.9, 123.8, 127.5, 
129.6, 129.9, 133.3, 138.7, 149.8, 162.5 (Ar-C), 178.6 (C=O), 178.6 
(C=O), 181.0 (C=O) ppm; MS (EI): m/z 348 (M-CHO2, 14%), 228 
(100), 227 (36), 171 (24), 145 (36), 119 (56), 92 (43), 91 (25), 77 
(22), 44 (14). HRMS (DIP): m/z [M–CHO2] calculated for 
C21H22N3O2: 348.1692; found: 348.1712.  
Methyl 1-isobutyl-4,6-dioxo-5-phenyl-3-(thiophen-2-
yl)octahydropyrrolo[3,4-c]pyrrole-1-carboxylate (4d): After 
19 hours and work up the product was isolated as a red pale solid 
(301 mg, 73 % yield); column chromatography (n-hexane:EtOAc; 
6:4); mp: 139 – 143 ºC. IR (ATR) υmax: 1710, 1501, 1384, 1236, 
1208, 1177, 1164, 822, 701, 692 cm-1; 1H NMR (300 MHz, CDCl3): 
δ 0.88 (d, J= 6.4 Hz, 3H), 1.01 (d, J= 6.4 Hz, 3H), 1.61-1.75 (m, 2H), 
2.03-2.24 (m, 1H), 3.37 (d, J = 7.6 Hz, 1H), 3.59 (dd, J = 9.2, 7.6 Hz, 
1H), 3.85 (s, OCH3), 5.00 (d, J = 9.1 Hz, 1H), 7.01 (dd, J = 5.1, 3.6 
Hz, 1 Ar-H), 7.11-7.43 (m, 7H, Ar-H) ppm; 13C NMR (101 MHz 
CDCl3): δ 22.1 (CH3), 24.3 (CH3), 24.4 (CH), 43.0 (CH2), 50.1 (CH), 
52.4 (CH3), 55.5 (CH), 57.9 (CH), 70.0 (C), 125.1, 125.4, 126.2, 
127.1, 128.5, 129.0, 131.6, 141.1 (Ar-C), 172.3 (C=O), 173.3 
(C=O), 174.6 (C=O) ppm; MS (EI): m/z 369 (M-C3H7, 2%), 357 (5), 
356 (22), 355 (34), 354 (23), 353 (100), 296 (11), 239 (45), 206 
(10), 197 (9), 196 (80), 179 (26), 162 (11), 149 (12) 136 (17), 
109 (15). HRMS (DIP): m/z [M+] calculated for C22H24N2O4S: 
412.1457; found: 412.1469.  
Methyl 6a-isobutyl-4,6-dioxo-5-phenyl-2-(thiophen-2-
yl)octahydropyrrolo[3,4-b]pyrrole-3-carboxylate (5d): After 
36 hours and work up the product was isolated as a sticky yellow 
oil (175 mg, 44 % yield); column chromatography (silica gel 
deactivate with 5% Et3N) (n-hexane:EtOAc; 6:4); IR (ATR) υmax: 
3340, 2956, 2926, 1708, 1378, 1198, 1139, 843, 689, 597 cm-1;  
1H NMR (300 MHz, MeOD): δ 0.95 (d, J= 6.4 Hz, 3H), 1.04 (d, J= 6.4 
Hz, 3H), 1.71-2.00 (m, 2H), 2.03-2.16 (m, 1H), 3.66 (dd, J = 4.7, 2.2 
Hz, 1H), 3.89 (d, J = 2.3 Hz, 1H), 5.05 (m, 1H), 6.76-6.69 (m, 2H, 
Ar-H), 6.92 (dd, J = 5.1, 3.5 Hz, 1Ar-H), 6.98 (d, J = 3.5 Hz, 1Ar-H), 
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7.25-7.43 (m, 4H, Ar-H) ppm; 13C NMR (75 MHz MeOD): δ 23.9 
(CH3), 24.7 (CH3), 26.5 (CH), 44.7 (CH2), 52.5 (CH), 53.5 (CH), 63.7 
(CH), 71.9 (C), 121.0, 125.0, 126.2, 127.8, 128.2, 129.8, 133.3, 
150.5 (Ar-C), 178.6 (2x C=O), 181.0 (C=O) ppm; MS (EI): m/z 310 
(M-C4H8O2), 278 (11), 277 (11), 251 (14), 209 (15), 207 (15), 206 
(100), 183 (23), 169 (80), 150 (19), 149 (17). HRMS (DIP): m/z 
[M+] calculated for C22H24N2O4S: 412.1457; found: 412.1452.  
Methyl 1-benzyl-4,6-dioxo-3,5-
diphenyloctahydropyrrolo[3,4-c]pyrrole-1-carboxylate 
(4e): After 18 hours and work up the product was isolated as a 
white solid (356 mg, 81 % yield); column chromatography (n-
hexane:EtOAc; 8:2); mp: 231-234 ºC. IR (ATR) υmax: 1750, 1716, 
1493, 1380, 1209, 1178, 1101, 853, 724, 703, 661 cm-1; 1H NMR 
(300 MHz, CDCl3): δ 2.35 (br s,1H, NH), 3.11 (d, J = 13.5 Hz, 1H), 
3.49 (d, J = 13.3 Hz, 1H), 3.61 (d, J = 7.6 Hz, 1H), 3.70 (dd, J = 9.4, 
7.6 Hz, 1H), 3.86 (s, 3H, OCH3), 4.96 (d, J = 9.4 Hz, 1H), 6.94-7.05 
(m, 2H, Ar-H), 7.11-7.18 (m, 2H, Ar-H), 7.25-7.41 (m, 9H, Ar-H), 
7.48-7.57 (m, 2H, Ar-H) ppm;13C NMR (101 MHz, CDCl3): δ 40.4 
(CH2), 49.15 (CH), 52.4 (CH3), 54.3 (CH), 61.3 (CH), 71.3 (C), 
126.1, 127.4, 127.6, 128.5, 128.6, 128.6, 128.9, 129.0, 129.5, 
131.4, 134.8, 137.2 (Ar-C), 171.5 (C=O), 173.8 (C=O), 174.9 (C=O) 
ppm; MS (EI): m/z 381 (M-C2H3O2, 3%), 350 (22), 349 (100), 202 
(14), 170 (13), 143 (11), 91 (15). HRMS (DIP): m/z [M+] 
calculated for C27H24N2O4, 440.1736; found: 440.1755.  
Methyl 6a-benzyl-4,6-dioxo-2,5-
diphenyloctahydropyrrolo[3,4-b]pyrrole-3-carboxylate 
(5e): After 37 hours and work up the product was isolated as a 
sticky yellow oil (194 mg, 44 % yield); column chromatography 
(silica gel deactivate with 5% Et3N) (n-hexane:EtOAc; 8:2); IR 
(ATR) υmax: 2918, 2849, 1711, 1455, 1377, 1259, 1173, 1028, 732, 
700, 691, 587 cm-1;  1H NMR (300 MHz, CDCl3): δ 3.16 (d, J = 12.8 
Hz, 1H), 3.63 (d, J = 12.8 Hz, 1H), 3.67 (dd, J = 4.0, 2.9 Hz, 1H), 3.77 
(d, J = 2.9 Hz, 1H), 3.83 (s, 3H, OCH3), 4.88 (d, J = 4.0 Hz, 1H), 6.37-
6.60 (m, 2H, Ar-H), 7.27-7.36 (m, 11H, Ar-H), 7.39-7.45 (m, 2H, 
Ar-H) ppm; 13C NMR (126 MHz, CDCl3): δ 40.7 (CH2), 50.3 (CH), 
53.0 (CH3), 54.2 (CH), 66.4 (CH), 71.6 (C), 126.4, 126.5, 127.8, 
128.2, 128.8, 129.0, 129.1, 130.5, 131.6, 134.9 (Ar-C), 173.1 
(C=O), 175.3 (C=O), 178.0 (C=O) ppm; MS (EI): m/z 349 (M-C7H7, 
14%), 317 (39), 289 (35), 234 (21), 178 (12), 177 (100), 170 
(19), 143 (12), 115 (16), 91 (43). HRMS (DIP): m/z [M+] 
calculated for C27H24N2O4, 440.1736; found: 440.1697.  
Methyl 1-benzyl-4,6-dioxo-5-phenyl-3-(pyridin-2-
yl)octahydropyrrolo[3,4-c]pyrrole-1-carboxylate (4f): After 
18 hours and work up the product was isolated as a white solid 
(388 mg, 87 % yield); column chromatography (n-hexane:EtOAc; 
6:4); mp: 197-200 ºC.  IR (ATR) υmax: 1710, 1495, 1395, 1212, 
1137, 1104, 1090, 859, 767, 729 cm-1;  1H NMR (300 MHz, CDCl3): 
3.11 (d, J = 13.7 Hz, 1H), 3.42 (d, J = 13.7 Hz, 1H), 3.63-.77 (m, 2H), 
3.85 (s, 3H, OCH3), 4.83 (d, J = 8.9 Hz, 1H), 7.04-7.16 (m, 2H, Ar-
H), 7.20-7.47 (m, 10H, Ar-H), 7.66 (td, J = 7.7, 1.8 Hz, 1H, Ar-H), 
8.53 (ddd, J = 4.9, 1.8, 0.9 Hz, 1H, Ar-H) ppm; 13C NMR (101 MHz, 
CDCl3): δ 42.0 (CH2), 51.4 (CH), 52.7 (CH3), 57.1 (CH), 64.8 (CH), 
73.5 (C), 123.6, 123.7, 126.5, 127.3, 128.5, 128.7, 129.1, 130.2, 
131.8, 135.8, 136.9, 149.3, 156.0 (Ar-C), 171.1 (C=O), 174.3 
(C=O), 174.9 (C=O) ppm;  MS (EI): m/z 382 (M-C2H3O2, 4%), 351 
(21), 350 (100), 193 (4). 177 (17), 171 (23), 145 (23), 143 (4), 
117 (6), 116 (5), 91 (13).  HRMS (DIP): m/z [M+] calculated for 
C26H23N3O4, 441.1689; found 441.1669. 
Methyl 6a-benzyl-4,6-dioxo-5-phenyl-2-(pyridin-2-
yl)octahydropyrrolo[3,4-b]pyrrole-3-carboxylate (5f): After 
36 hours and work up the product was isolated as a Sticky yellow 
oil (238 mg, 54 % yield); column chromatography (silica gel 
deactivate with 5% Et3N) (n-hexane:EtOAc; 6:4); IR (ATR) υmax: 
2923, 2853, 1709, 1592, 1378, 1178, 1051, 744, 702, 590 cm-1;  
1H NMR (300 MHz, CDCl3): 3.18 (d, J = 12.8 Hz, 1H), 3.60 (d, J = 
12.9 Hz, 1H), 3.87 (s, 3H, OCH3), 3.89 (d, J = 2.0 Hz, 1H), 4.11-4.15 
(m, 1H), 5.04 (d, J = 2.7 Hz, 1H), 6.48-6.70 (m, 2H, Ar-H), 6.90-7.53 
(m, 9H, Ar-H), 7.54 (d, J = 7.8 Hz, 1H, Ar-H), 7.66-7.77 (m, 1H, Ar-
H), 8.49 (ddd, J = 4.9 Hz, 1H, Ar-H) ppm; 13C NMR (126 MHz, 
CDCl3): δ 41.8 (CH2), 49.9 (CH), 52.5 (CH), 53.19 (CH3), 67.1 (CH), 
72.3 (C), 121.6, 123.1, 126.1, 127.7, 128.6, 128.9, 130.4, 131.5, 
135.0, 138.0, 148.7, 159.2 (Ar-C), 173.1 (C=O), 175.2 (C=O), 178.3 
(C=O) ppm;MS (EI): m/z 382 (M+-C2H3O2, 51%), 350 (100), 235 
(14), 177 (19), 171 (22), 145 (24), 119 (28), 117 (19), 93 (21), 
92(22), 91 (52), 78 (14), 44 (23). HRMS (DIP): m/z [M+] 
calculated for C26H23N3O4, 441.1689; found 441.1698.  
Methyl (1S,3R)-1-((1H-indol-3-yl)methyl)-5-methyl-4,6-
dioxo-3-phenyloctahydropyrrolo [3,4-c]pyrrole-1-
carboxylate (4gb): After 26 h and work up the product (317 mg, 
76 % yield) was crystallised as colourless prisms: mp 232-234 ºC 
(dec.); IR νmax: 3358, 2981, 2884, 1776, 1732, 1685, 1440, 1387, 
1285, 1200, 1103, 1078, 963, 843, 727, 701, 654 cm-1; 1H NMR 
(400 MHz, DMSO): δ 10.98 (bs, 1H, NH), 7.55 (d, 1H, J = 7.88 Hz, 
Ar-H), 7.36-6.96 (m, 9H, Ar-H), 5.00 (dd, 1H, J = 9.40 Hz, 5.16 Hz, 
5-H), 3.74 (dd, 1H, J = 9.20 Hz, 7.64 Hz, 4-H), 3.69 (s, 3H, OCH3), 
3.62 (d, 1H, J = 7.40 Hz, 3-H), 3.44 (d, 1H, J = 14.56 Hz, 6-H), 3.34 
(d, 1H, J = 14.50 Hz, 6-H'), 2.66 (s, 3H, NCH3), 2.36 (d, 1H, J = 5.02 
Hz, NH) ppm; 13C NMR (100 MHz, DMSO): δ 176.1 (C=O), 174.9 
(C=O), 171.7 (C=O), 139.1, 135.9, 127.9 (2 x C), 127.5, 127.4, 
127.3 (2 x C), 124.3, 120.9, 118.5, 118.1, 111.4, 107.9, 70.2, 59.7, 
53.78, 51.5, 49.0, 30.2, 24.2 ppm; MS (ESI, M+H+): m/z 418.3 
(M+H+, 100) ; HRMS (DIP): m/z [M+] calculated for C24H23N3O4, 
417.1694; found: 417.1689.  
Methyl (1S,3R)-1-((1H-indol-3-yl)methyl)-4,6-dioxo-5-
phenyl-3-(pyridin-2-yl) octahydropyrrolo [3,4-c] pyrrole-1-
carboxylate (4gc): After 26 h and work up the product (384 mg, 
80 % yield) was isolated as colourless prisms: mp 231-233 ºC 
(dec.); IR  νmax:  3381, 3350, 3061, 2959, 2878, 1779, 1707, 1614, 
1591, 1489, 1435, 1384, 1323, 1204, 1178, 1101, 739, 686 cm-1; 
1H NMR (400 MHz, DMSO): δ 10.86 (bs, 1H, NH), 8.59-8.57 (m, 
1H, Ar-H), 7.85-6.97 (m, 13H, Ar-H), 5.16 (dd, 1H, J = 11.22 Hz, 
9.26 Hz, 5-H), 3.97 (dd, 1H, J = 9.16 Hz, 7.64 Hz, 4-H), 3.89 (d, 1H, 
J = 7.60 Hz, 3-H), 3.79 (d, 1H, J = 11.24 Hz, NH), 3.68 (s, 3H, OCH3), 
3.47 (d, 1H, J = 14.68 Hz, 6-H), 3.30 (d, 1H, J = 14.60 Hz, 6-H') ppm; 
13C NMR (100 MHz, DMSO): δ 175.2 (C=O), 174.4 (C=O), 171.7 
(C=O), 156.4, 148.8, 136.8, 135.6, 132.2, 128.8 (2 x C), 128.2, 
128.1, 126.7 (2 x C), 124.3, 123.9, 123.3, 120.6, 118.6, 118.2, 
111.2, 109.2, 70.0, 63.4, 57.4, 51.8, 51.4, 31.1 ppm; MS (ESI, 
M+H+): m/z 481.2 (M+H+, 100); HRMS (DIP): m/z [M+] calculated 
for C28H24N4O4, 480.1798; found: 480.1702 
Methyl(1S,3R)-1-((1H-indol-3-yl)methyl)-5-methyl-4,6-
dioxo-3-(pyridin-2-yl) octahydropyrrolo [3,4-c]pyrrole-1-
carboxylate (4gd): After 26 h and work up the product (313 mg, 
75 % yield) was isolated and crystallised as colourless prisms: 
mp 229-231 ºC (dec.); IR νmax: 3359, 3300, 2981, 1774, 1735, 
1682, 1595, 1443, 1289, 1224, 1095, 995,  727 cm-1; 1H NMR (400 
MHz, DMSO): 10.82 (bs, 1H, NH), 8.49-8.44 (m, 1H, Ar-H), 7.785-
Synthesis Article 
Template for SYNTHESIS © Thieme, Stuttgart · New York 2019-03-20 page 9 of 12 
6.92 (m, 8H, Ar-H), 5.02 (dd, 1H, J = 11.04 Hz, 9.32 Hz, 5-H), 3.97 
(dd, 1H, J = 9.14 Hz, 7.54 Hz, 4-H), 3.67 (s, 3H, OCH3), 3.65 (d, 1H, 
J = 7.48 Hz, 3-H), 3.55 (d, 1H, J = 11.12 Hz, NH), 3.39 (d, 1H, J = 
14.92 Hz, 6-H), 3.21 (d, 1H, J = 14.84 Hz, 6-H'), 2.61 (s, 3H, NCH3) 
ppm; 13C NMR (100 MHz, DMSO): δ 176.0 (C=O), 175.2 (C=O), 
171.7 (C=O), 156.4, 148.7, 136.6, 135.5, 128.0, 124.2, 123.7, 
123.0, 120.6, 188.5, 118.2, 111.1, 109.1, 72.6, 62.9, 57.0, 51.8, 
51.3, 30.9, 24.3 ppm; MS (ESI, M+H+): m/z 419.2 (M+H+, 100); 




pyrrole-1-carboxylate (4ge): After 26 h and work up the 
product (349 mg, 68 % yield) was isolated and crystallised as 
colourless prisms: mp 273-275 ºC (dec.); IR νmax: 3335, 2981, 
1779, 1708, 1598, 1573, 1433, 1385, 1202, 1181, 1100, 954, 748, 
689 cm-1;  1H NMR (400 MHz, DMSO): δ 11.02 (bs, 1H, NH), 7.58-
6.98 (m, 9H, Ar-H), 5.14 (dd, 1H, J = 9.46 Hz, 4.50 Hz, 5-H), 3.91 
(dd, 1H, J = 9.48 Hz, 7.64 Hz, 4-H), 383 (dd, 1H, J = 7.56 Hz, 1.60 
Hz, 3-H), 3.66 (s, 3H, OCH3), 3.50 (d, 1H, J = 14.56 Hz, 6-H), 3.35 
(d, 1H, J = 14.52 Hz, 6-H'), 2.69 (d, 1H, J = 4.36 Hz, NH) ppm;  13C 
NMR (100 MHz, DMSO): δ 175.3 (C=O), 174.0 (C=O), 171.6 (C=O), 
142.0, 135.9, 132.7, 132.0, 129.8, 128.8 (2 x C), 128.2, 127.5 (2 x 
C), 127.1, 126.5 (2 x C), 126.4, 124.6, 121.0, 118.5, 118.0, 111.4, 
107.6, 70.3, 59.0, 53.7, 51.5, 48.7, 30.3 ppm; MS (ESI, M+H+): m/z 
512.2 (M+H+, 100), 514.2 (M+H+, 35); HRMS (DIP): m/z [M+] 
calculated for C29H24ClN3O4, 513.1455; found: 513.1442 
Methyl(1S,3R)-1-((1H-indol-3-yl)methyl)-3-(3-
chlorophenyl)-5-methyl-4,6-dioxooctahydropyrrolo[3,4-
c]pyrrole-1-carboxylate (4gf): After 26 h and work up the 
product ( 307 mg, 68 % yield) was isolated and crystallised as 
colourless prisms: mp 251-253 ºC (dec.); IR νmax: 3339, 3324, 
3062, 2949, 2926, 1782, 1704, 1672, 1426, 1290, 1203, 1099, 
1081,755, 748 cm-1; 1H NMR (400 MHz, δ 10.99 (bs, 1H, NH), 
7.54-6.96 (m, 9H, Ar-H), 5.01 (dd, 1H, J = 9.38 Hz, 4.66 Hz, 5-H), 
3.75 (dd, 1H, J = 9.30 Hz, 7.54 Hz, 4-H), 3.68 (s, 3H, OCH3), 3. 62 
(dd, 1H, J = 7.40 Hz, 1.32 Hz, 3-H), 3.45 (d, 1H, J = 14.60 Hz, 6-H), 
3.29 (d, 1H, J = 14.56 Hz, 6-H')  2.66 (s, 3H, NCH3) ppm; 13C NMR 
(100 MHz, DMSO): δ 176.0 (C=O), 174.9 (C=O), 171.5 (C=O), 
142.0, 135.9, 132.5, 129.7, 127.4, 127.3, 127.9, 126.0, 124.5, 
121.0, 118.5, 118.0, 111.4, 107.7, 70.1, 58.8, 53.4, 51.5, 48.7, 30.2, 
24.2 ppm; MS (ESI, M+H+): m/z 452.2 (M+H+, 100), 454.2 (M+H+, 
35); HRMS (DIP): m/z [M+] calculated for C24H22ClN3O4, 
451.1299; found: 451.1293. 
 (1S,3R)-methyl1-((1H-indol-3-yl)methyl)-3-(4-
chlorophenyl)-5-ethyl-4,6-dioxo-octahydropyrrolo[3,4-
c]pyrrole-1-carboxylate (4gg): After 26 h and work up the 
product (340 mg, 73 % yield) was isolated and crystallised as 
colourless prisms: mp 237-239 ºC (dec.); IR  νmax: 3339, 2981, 
2944, 2840, 1774 (C=O), 1739 (C=O), 1683 (C=O), 744cm-1; 1H 
NMR (400 MHz, DMSO): δ 11.00 (brs, 1H, NH), 7.54 (d, 1H, J= 7.88 
Hz, ArH), 7.35-7.33 (m, 5H, ArH), 7.17-6.96 (m, 3H, ArH), 5.02 (dd, 
1H, J= 4.68 Hz, J= 9.4 Hz, 5H), 3.72 (d, 1H, J= 7.6 Hz, CHHCH3), 
3.68(s, 3H, OCH3),3.60 (d, 1H, J= 7.48 Hz, CHHCH3), 3.43 (d, 1H, J= 
14.6 Hz, 6H), 3.30 (d, 1H, J= 14.56 Hz,  6'H), 3.25-3.13 (m, 2H, 3H 
and NH), 3.44 (s, 1H, NH), 2.42 (d, 1H, J= 3.56 Hz, 4H), 0.91(t, 3H, 
J= 7.16 Hz, CH2CH3) ppm; 13C NMR (100 MHz, DMSO): δ 175.7 
(C=O), 174.6 (C=O), 171.5 (C=O), 138.1, 135.9, 131.8, 129.2 (2 x 
C), 127.7 (2 x C), 127.5, 124.4, 120.9, 118.5, 118.0, 111.4, 107.8, 
70.2, 58.8, 53.4, 51.5, 48.5, 32.9, 30.2, 12.7 ppm; MS (ESI, M+H+): 
m/z 466.3 (M+, 100, Cl: 35) /468.3 (M+, 33.3, Cl: 37)-(3/1) and 
467.3 (M+1, 100, Cl: 35)  /469.3(M+1, 33.3, Cl: 37) -(3/1); HRMS 
(DIP): m/z [M+] calculated for C25H24ClN3O4, 465.1451; found: 
465.1455. 
Methyl (2S, 3S, 6aR)-6a-((1H-indol-3-yl)methyl)-5-methyl-
4,6-dioxo-2-phenyl octahydro pyrrolo[3,4-b]pyrrole-3-
carboxylate (5gb): After 36 h and work up the product (400 mg, 
96 % yield) was isolated and crystallised as colourless prisms: 
mp 151-153 ºC; IR νmax: 3355, 3059, 2981, 2889, 1710, 1595, 
1495, 1436, 1383, 1195, 1011, 744 cm-1;  1H NMR (400 MHz, 
DMSO): δ11.00 (bs, 1H, NH), 7.70 (d, 1H, J = 7.76 Hz, Ar-H), 7.40-
7.02 (m, 9H, Ar-H), 4.66 (dd, 1H, J = 5.90 Hz, 5.90 Hz, 2-H), 4.06 
(d, 1H, J = 5.36 Hz, NH), 3.54 (s, 3H, OCH3), 3.50 (d, 1H, J = 4.96 Hz, 
4-H), 3.42 (d, 1H, J = 14.20 Hz, 6-H), 3.22 (d, 1H, J = 14.24 Hz, 6-
H’), 3.12 (dd, 1H, J = 6.18 Hz, 5.14 Hz, 3-H),  2.59 (s, 3H, NCH3) 
ppm; 13C NMR (100 MHz, DMSO): δ 178.9 (C=O), 176.1 (C=O), 
171.5 (C=O), 143.9, 135.9, 132.9, 130.0, 127.4, 127.3, 126.2, 
125.2, 124.7, 121.0, 118.6, 118.2, 111.5, 107.6, 70.9, 65.3, 54.1, 
52.1, 51.1, 28.8, 24.4 ppm; MS (ESI, M+H+): m/z 417.4 (M+H+, 
100); HRMS (DIP): m/z [M+] calculated for C24H23N3O4, 417.1694; 
found: 417.1688.  
Methyl(2S,3S,6aR)-6a-((1H-indol-3-yl)methyl)-4,6-dioxo-5-
phenyl-2-(pyridin-2-yl)octahydropyrrolo[3,4-b]pyrrole-3-
carboxylate (5gc): After 36 h and work up the product (441 mg, 
92 % yield) was isolated and crystallised as colourless prisms: 
mp 219-221 ºC (dec.);  IR νmax: 3352, 3058, 2981, 1712, 1595, 
1541, 1436, 1383, 1099, 744 cm-1; 1H NMR (400 MHz, DMSO): δ 
10.91 (bs, 1H, NH), 8.72 (brd, 1H, J = 4.16 Hz, Ar-H), 7.80-6.94 (m, 
13H, Ar-H), 4.45 (dd, 1H, J = 8.24 Hz, 8.20 Hz, 2-H), 3.67-3.60 (m, 
2H, 3-H, 6-H), 3.43 (s, 3H, OCH3), 3.39-3.30 (m, 2H, 4-H, 6-H’) 
ppm; 13C NMR (100 MHz, DMSO): δ 178.8 (C=O), 175.1 (C=O), 
172.7 (C=O), 160.2, 148.6, 136.9, 136.0, 131.6, 128.6 (2 x C), 
128.2, 127.4, 126.1 (2 x C), 124.7, 122.5, 121.3, 121.1, 118.7, 
118.3, 111.6, 107.5, 72.5, 66.9, 52.3, 51.7, 51.1, 20.2 ppm; MS (ESI, 
M+H+): m/z 481.2 (M+H+, 100); HRMS (DIP): m/z [M+] calculated 
for C28H24N4O4, 480.1798; found: 480.1704. 
Methyl(2S,3S,6aR)-6a-((1H-indol-3-yl)methyl)-5-methyl-
4,6-dioxo-2-(pyridin-2-yl)octahydropyrrolo[3,4-b]pyrrole-
3-carboxylate (5gd): After 36 h and work up the product (355 
mg, 85 % yield) was isolated and crystallised as colourless 
prisms: mp 198-200 ºC (dec.); IR  νmax: 3355, 2981, 2972, 2889, 
1975, 1774, 1698, 1520, 1432, 1380, 1251, 1150, 1073, 955, 775, 
741 cm-1;   1H NMR (400 MHz, DMSO): δ 10.97 (bs, 1H, NH), 8.40-
8.38 (m, 1H, Ar-H), 7.75-7.67 (m, 2H, Ar-H), 7.47-6.99 (m, 6H, Ar-
H), 4.78 (dd, 1H, J = 4.74 Hz, 3.34 Hz, 2-H), 4.07 (d, 1H, J = 5.36 Hz, 
NH), 3.79 (dd, 1H, J = 3.01 Hz, 2.76 Hz, 3-H), 3.57 (s, 3H, OCH3), 
3.47 (d, 1H, J = 2.64 Hz, 4-H), 3.39 (d, 1H, J = 14.08 Hz, 6-H), 3.15 
(d, 1H, J = 14.08 Hz, 6-H'),  2.33 (s, 3H, NCH3) ppm; 13C NMR (100 
MHz, DMSO): δ 179.5 (C=O), 176.1 (C=O), 172.5 (C=O), 159.9, 
148.5, 136.6, 135.8, 127.4, 124.6, 122.3, 121.0, 120.9, 118.6, 
118.1, 111.5, 107.6, 72.1, 66.7, 52.2, 51.7, 50.8, 29.5, 24.1 ppm; 
MS (ESI, M+H+): m/z 419.2 (M+H+, 100). HRMS (DIP): m/z [M+] 
calculated for C23H22N4O4, 418.1641; found: 418.1649. 
Methyl(2S,3S,6aR)-6a-((1H-indol-3-yl)methyl)-2-(3-
chlorophenyl)-4,6-dioxo-5-phenyloctahydropyrrolo[3,4-
b]pyrrole-3-carboxylate (5ge): After 36 h and work up the 
product (503 mg, 98 % yield) was isolated and crystallised as 
colourless prisms: mp 169-171 ºC; IR νmax: 3315, 3060, 2983, 
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2950, 1782, 1739, 1703, 1595, 1436, 1392, 1253, 1240, 1164, 
981, 747 cm-1; 1H NMR (400 MHz, DMSO): δ 11.08 (bs, 1H, NH), 
7.75 (d, 1H, J = 7.80 Hz, Ar-H),  7.53-6.64 (m, 13H, Ar-H), 4.78 (dd, 
1H, J = 5.42 Hz, 5.42 Hz, 2-H), 4.24 (d, 1H, J = 5.48 Hz, NH), 3.72 
(d, 1H, J = 4.44 Hz, 4-H), 3.58 (s, 3H, OCH3), 3.55 (d, 1H, J = 14.12 
Hz, 6-H), 3.43 (dd, 1H, J = 5.42 Hz, 4.48 Hz, 3-H), 3.30 (d, 1H, J = 
14.18 Hz, 6-H’) ppm; 13C NMR (100 MHz, DMSO): δ 179.1 (C=O), 
176.3 (C=O), 173.1 (C=O), 145.3, 137.5, 134.8, 133.3, 131.0, 129.4 
(2 x C), 129.1, 128.7, 128.4, 127.5 (2 x C), 127.4, 126.0, 125.8, 
122.5, 120.0, 119.6, 112.4, 109.3, 72.7, 66.6, 55.9, 52.8, 52.5, 30.5. 
MS (ESI, M-H+):  m/z 512.2 (M+H+, 100), 514.2 (M+H+, 35). HRMS 




b]pyrrole-3-carboxylate (5gf): After 26 h and work up the 
product (429 mg, 95 % yield) was isolated and crystallised as 
colourless prisms: mp 152-154 ºC ; IR νmax: 3344, 3270, 3060, 
2982, 2949, 1780, 1737, 1705, 1378, 1288, 1173,  747, 681 cm-1; 
1H NMR (400 MHz, DMSO): δ 11.00 (bs, 1H, NH), 7.70 (d, 1H, J = 
7.76 Hz, Ar-H), 7.40-7.02 (m, 8H, Ar-H), 4.66 (dd, 1H, J = 5.68 Hz, 
5.68 Hz, 2-H), 4.06 (d, 1H, J = 5.28 Hz, NH), 3.54 (s, 3H, OCH3), 3.50 
(d, 1H, J = 4.88 Hz, 4-H), 3.43 (d, 1H, J = 14.20 Hz, 6-H), 3.22 (d, 
1H, J = 14.20 Hz, 6-H’) ), 3.13 (dd, 1H, J = 6.36 Hz, 4.96 Hz, 3-H), 
2.59 (s, 3H, NCH3) ppm; 13C NMR (100 MHz, DMSO): δ 178.8 
(C=O), 176.1 (C=O), 171.5 (C=O), 143.9, 135.9, 132.9, 130.0, 
127.4, 127.3, 126.2, 125.2, 124.7, 121.0, 118.6, 118.2, 111.5, 
107.6, 70.9, 65.3, 54.1, 52.1, 51.1, 28.8, 24.1 ppm; MS (ESI, M+H+): 
m/z 452.2(M+H+, 100), 454.2(M+H+, 35). HRMS (DIP): m/z [M+] 




(6ga): After 24 h and work up the product (552 mg, 86 % yield) 
was isolated and crystallised as pale yellow prisms: mp 150-152 
ºC; IR νmax: 3202, 3060, 2981, 2889, 1787, 1739, 1702, 1537, 
1492, 1389, 1252, 1202, 923, 743, 704 cm-1; 1H NMR (400 MHz, 
DMSO): δ 11.60 (bs, 1H, NH), 11.33 (bs, 1H, NH), 8.11 (d, 2H, J = 
7.40 Hz, Ar-H), 7.72-7.00 (m, 17H, Ar-H), 6.80 (bs, 1H, 2-H), 4.22 
(d, 1H, J = 1.44 Hz, 4-H), 3.91 (brs, 2H, 6-H ve 6-H’), 3.46 (dd, 1H, 
J = 1.76 Hz, 1.76 Hz 3-H), 2.78 (s, 3H, OCH3) ppm; 13C NMR (100 
MHz, DMSO): δ 179.7 (C=S), 176.4 (C=O), 173.9 (C=O), 168.7 
(C=O), 165.1 (C=O), 138.5,  135.4, 133.3, 133.0, 130.8, 129.2, 
129.6 (2 x C), 129.0 (2 x C), 128.8 (2 x C), 127.8 (2 x C), 127.8, 
127.3, 126.5 (2 x C), 126.2, 125.1 (2 x C), 121.1, 118.8, 118.1, 
111.4, 104.5, 74.2, 69.2, 54.2, 51.5, 50.1, 26.7 ppm; MS (ESI, 
M+H+): m/z 643.2 (M+H+, 100); HRMS (DIP): m/z [M+] calculated 




(6gb): After 24 h and work up the product (516 mg, 89 % yield) 
was isolated and crystallised as pale yellow prisms: mp 207-209 
ºC; IR νmax: 3267, 3187, 3060, 3027, 2885, 1786, 1741, 1686, 
1546, 1445, 1225, 955, 703 cm-1;  1H NMR (400 MHz, DMSO): δ 
11.74 (bs, 1H, NH), 11.25 (bs, 1H, NH),  8.12 (d, 2H, J = 7.24 Hz, 
Ar-H), 7.73-7.59 (m, 4H, Ar-H), 7.38-6.98 (m, 9H, Ar-H), 6.64 (brs, 
1H, 2-H), 3.97 (d, 1H, J = 1.84 Hz, 4-H), 3.76 (brs, 2H, 6-H ve 6-H’), 
3.24 (dd, 1H, J = 2.16 Hz, 2.16 Hz, 3-H),  2.81 (s, 3H, OCH3), 2.75 
(s, 3H, NCH3) ppm; 13C NMR (100 MHz, DMSO): δ 178.8 (C=S), 
178.0 (C=O), 174.6 (C=O), 168.7 (C=O), 164.9 (C=O), 138.7, 135.4, 
133.3, 133.1, 129.1 (2 x C), 128.6 (2 x C), 127.8 (2 x C), 127.7, 
127.2, 126.0, 124.8 (2 x C), 121.1, 118.8, 118.0, 111.4, 104.5 74.2, 
69.2, 53.9, 51.5, 50.0, 26.2, 25.3 ppm; MS (ESI, M+H+): m/z 580.6 
(M+H+, 100); HRMS (DIP): m/z [M+] calculated for C32H28N4O5S, 




After 30 h and work up the product (489 mg, 76 % yield) was 
isolated and crystallised as pale yellow prisms: mp 170-172 ºC;  
IR νmax: 3357, 2981, 1782, 1755, 1738, 1698, 1538, 1255, 1238, 
743,706 cm-1; 1H NMR (400 MHz, DMSO): δ 11.92 (bs, 1H, NH), 
11.33 (bs, 1H, NH), 8.45-8.43 (m, 1H, Ar-H),  8.01-7.06 (m, 18H, 
Ar-H), 6.56 (brs, 1H, 2-H), 4.25 (s, 1H, 4-H), 3.90 (d, 1H, J = 15.06 
Hz, 6-H), 3.84 (d, 1H, J = 15.12 Hz, 6-H’), 3.24 (s, 1H, 3-H), 2.73 (s, 
3H, OCH3) ppm; 13C NMR (100 MHz, DMSO): δ 176.6 (C=S), 176.5 
(C=O), 173.2 (C=O), 167.5 (C=O), 163.6 (C=O), 156.8, 148.2, 
135.7, 134.2, 132.0, 131.9, 130.2, 128.1 (2 x C), 128.1, 128.0 (2 x 
C), 126.6, 126.4 (2 x C),  125.4 (2 x C), 124.9, 122.8, 121.9, 120.0, 
117.6, 117.1, 110.2, 103.4, 73.0, 69.5, 53.4, 50.4, 46.4, 25.8 ppm; 
MS (ESI, M+H+): m/z 644.2 (M+H+, 100);  HRMS (DIP): m/z [M+] 




After 24 h and work up the product (453 mg, 78 % yield) was 
isolated and crystallised as pale yellow prisms: mp 198-200 ºC; 
IR νmax: 3170, 3060, 2961, 1785, 1755, 1738, 1685, 1553, 1449, 
1357, 1233, 1007, 748,705 cm-1;   1H NMR (400 MHz, DMSO): δ 
11.99 (bs, 1H, NH), 11.25 (bs, 1H, NH), 8.41-8.39 (m, 1H, Ar-H),   
8.02-8.00 (m, 2H, Ar-H), 7.76-7.60 (m, 5H, Ar-H), 7.37-7.00 (m, 
6H, Ar-H), 6.56 (d, 1H, J = 1.24 Hz 2-H), 3.99 (d, 1H, J = 1.36 Hz, 4-
H), 3.35 (brs, 2H, 6-H ve 6-H’), 3.07 (s, 3H, OCH3), 3.07-3.05 (m, 
1H, 3-H),  2.65 (s, 3H, NCH3) ppm; 13C NMR (100 MHz, DMSO): δ 
178.9 (C=S), 177.5 (C=O), 175.3 (C=O), 168.7 (C=O), 164.7 (C=O), 
157.8, 149.4, 136.7, 135.4, 133.2, 133.1, 129.1 (2 x C), 127.7, 
127.6 (2 x C), 125.9, 123.6, 122.9, 121.0, 118.8, 118.0, 111.3, 
104.7, 74.1, 70.4, 54.5, 51.5, 47.5, 26.5, 25.5. MS (ESI, M+H+): m/z 
581.6 (M+H+, 100); HRMS (DIP): m/z [M+] calculated for 




After 24 h and work up the product (554 mg, 82 % yield) was 
isolated and crystallised as pale yellow prisms: mp 157-159 ºC; 
IR νmax: 3387, 3196, 3051, 2956, 1787, 1704, 1529, 1491, 1348,  
1255, 1191, 755, 699 cm-1;  1H NMR (400 MHz, DMSO): δ 11.51 
(bs, 1H, NH), 11.31 (bs, 1H, NH), 8.09 (d, 2H, J = 7.24 Hz, Ar-H), 
7.71-7.03 (m, 17H, Ar-H), 6.69 (bs, 1H, 2-H), 4.22 (d, 1H, J = 1.84 
Hz, 4-H), 3.91 (brs, 2H, 6-H ve 6-H’), 3.44 (dd, 1H, J = 2.30 Hz, 2.30 
Hz 3-H),  2.76 (s, 3H, OCH3) ppm; 13C NMR (100 MHz, DMSO): δ 
180.5 (C=S), 175.5 (C=O), 173.8 (C=O), 168.5 (C=O), 165.4 (C=O), 
141.5, 135.5, 133.5, 133.3, 132.9, 130.9, 130.6, 129.2, 129.1 (2 x 
C), 128.9 (2 x C), 127.9 (2 x C), 127.8, 127.4, 126.4 (2 x C), 126.1, 
125.2, 124.0, 121.1, 118.8, 118.1, 111.4, 104.5, 74.7, 69.2, 54.1, 
51.6, 49.9, 26.7 ppm; MS (ESI M+H+): m/z 678.2 (M+H+, 100), 
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679.2 (M+H+, 35); HRMS (DIP): m/z [M+] calculated for 




After 24 h and work up the product (538 mg, 84 %) was isolated 
and crystallised as pale yellow prisms: mp 192-194 ºC; IR νmax: 
3384, 3203, 2982, 2951, 1784, 1745, 1693, 1537, 1365, 1352, 
1254, 1237, 1213, 752, 693 cm-1;   1H NMR (400 MHz, DMSO): δ 
11.67 (bs, 1H, NH), 11.24 (bs, 1H, NH), 8.10 (d, 2H, J = 7.40 Hz, Ar-
H), 7.73-7.56 (m, 4H, Ar-H), 7.37-7.23 (m, 4H, Ar-H), 7.11-6.95 
(m, 4H, Ar-H), 6.53 (bs, 1H, 2-H), 3.96 (d, 1H, J = 1.88 Hz, 4-H), 
3.75 (brs, 2H, 6-H ve 6-H’), 3.26 (dd, 1H, J = 2.36 Hz, 2.36 Hz 3-H),  
2.84 (s, 3H, OCH3), 2.74 (s, 3H, NCH3) ppm; 13C NMR (100 MHz, 
DMSO): δ 179.2 (C=S), 177.5 (C=O), 174.5 (C=O), 168.5 (C=O), 
165.0 (C=O), 141.4, 135.4, 133.4, 133.2, 133.1, 130.5, 129.0 (2 x 
C), 127.8 (2 x C), 127.6, 127.3, 125.9, 125.2, 123.5, 121.1, 118.8, 
117.9, 111.4, 104.5, 74.5, 69.0, 53.8, 51.6, 49.7, 26.3, 25.3 ppm; 
MS (ESI, M+H+): m/z 615.2 (M+H+, 100), 616.1 (M+H+, 35); HRMS 
(DIP): m/z [M+] calculated for C32H27ClN4O5S, 614.1391; found: 
614.1386. 
 
General Procedure Compound 7gg 
To a stirred solution of bicyclic pyrrolidine 4gg (0,4 g, 0,85mmol) 
in MeOH (not anhydrous, 20 mL) was added dropwise a solution 
of sodium methoxide (0,38 g, 2,04 mmol) in dry MeOH (10 mL) 
over 10 min and the mixture stirred and heated at reflux 
temperature for 36 h. The solvent was evaporated under reduced 
pressure, quenched with saturated aqueous ammonium chloride 
then extracted thrice with CH2Cl2. The combined organic solvents 
were dried over MgSO4 and filtered. The product 7gg (0,13g, 
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